139756-08-4

Basic information

• Product Name: 4-Nitro-3-propyl-1H-pyrazole-5-carboxamide
• Synonyms: 4-Nitro-3-propyl-1H-pyrazole-5-carboxamide
• CAS NO: 139756-08-4
• Molecular Formula: C₇H₁₀N₄O₃
• Molecular Weight: 198.1793
• Mol File: 139756-08-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Nitro-3-propyl-1H-pyrazole-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Nitro-3-propyl-1H-pyrazole-5-carboxamide(139756-08-4)
• EPA Substance Registry System: 4-Nitro-3-propyl-1H-pyrazole-5-carboxamide(139756-08-4)

Safety Data

• Hazardous Substances Data: 139756-08-4(Hazardous Substances Data)

Upstream product

• 76424-48-1 4-Nitro-3-n-propyl-1H-pyrazole-5-carboxylic Acid 
• 76424-47-0 3-n-propyl-1H-pyrazolo-5-carboxylic acid 
• 36983-31-0 ethyl 3-butyrylpyruvate 
• 1336-21-6 ammonium hydroxide 

Downstream Products

• 76424-56-1 4-Amino-3-n-propyl-1H-pyrazole-5-carboxamide 
• 139756-30-2 5-(2-ethoxyphenyl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one 
• 139756-10-8 4-(2-ethoxybenzamido)-3-n-propyl-1H-pyrazolo-5-carboxamide 

Relevant articles and documents

Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors

Several different heterocyclic systems were compared as PDE5 inhibitor scaffolds. In addition to the known 3H-imidazo[5,1-f][1,2,4]triazin-4-ones and pyrazolopyrimidinones, isomeric imidazo[1,5-a][1,3,5]triazin-4(3H)-ones were also shown to be potent and selective PDE inhibitor scaffolds with in vivo activity. SAR trends were elucidated for sulfonamide derivatives with generality across different scaffolds.

Novel process for the preparation of pyrazoles

A “one-pot” process is described herein for the production of pyrazole compounds of general formula (II) comprising the steps of reacting a compound of general formula (III) with an acylating agent in the presence of a base and an optional activating agent followed by the addition of a hydrazine compound in situ.

Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction

Compounds of the formulae (IA) and (IB): wherein R1is C1to C3alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1to C4alkoxy; halo; CN; CF3; OCF3or C1to C4alkyl wherein said C1to C4alkyl group is optionally substituted by C1to C4haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2is C1to C6alkyl and R13is OR3or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).